A 55-year-old cisgender woman was recently diagnosed with HIV, with an initial CD4 count of 349 cells/mm³ and an HIV RNA level of 158,780 copies/mL. She is now being seen in clinic 4 weeks later and the plan is to start antiretroviral therapy. There is no evidence of resistance on the baseline genotype resistance assay. You are considering using either tenofovir DF-emtricitabine, tenofovir alafenamide-emtricitabine, or abacavir-lamivudine as the nucleoside reverse transcriptase inhibitor (NRTI) backbone, in combination with a third anchor drug.